Tobin Schilke's Insider Trades & SAST Disclosures
Tobin Schilke's most recent trade in Crinetics Pharmaceuticals Inc was a trade of 80,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Tobin Schilke.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc | Tobin C. Schilke | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Tobin C. Schilke | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 52,000 | 52,000 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 6,888 | 201,554 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 2.18 per share. | 31 Dec 2024 | 1,000 | 194,666 (0%) | 0% | 2.2 | 2,185 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 2.18 per share. | 30 Jun 2024 | 1,000 | 193,666 (0%) | 0% | 2.2 | 2,185 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 5.04 per share. | 15 Mar 2024 | 9,361 | 192,666 (0%) | 0% | 5.0 | 47,204 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 15 Mar 2024 | 3,822 | 202,027 (0%) | 0% | 5.3 | 20,276 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 17,447 | 205,849 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Schilke Tobin C. | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 145,001 | 145,001 | - | - | Performance Stock Units | |
| Revance Therapeutics Inc | C. Tobin Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 96,667 | 188,402 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | C. Tobin Schilke | CFO | Grant, award, or other acquisition of securities at price $ 7.47 per share. | 31 Dec 2023 | 434 | 91,735 (0%) | 0% | 7.5 | 3,242 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 22,620 | 102,516 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.91 per share. | 11 Aug 2023 | 11,215 | 91,301 (0%) | 0% | 18.9 | 212,076 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 30 Jun 2023 | 1,701 | 79,896 (0%) | 0% | 25.0 | 42,593 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 15.61 per share. | 30 Jun 2023 | 769 | 81,597 (0%) | 0% | 15.6 | 12,001 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 30.57 per share. | 01 Jun 2023 | 2,701 | 81,328 (0%) | 0% | 30.6 | 82,570 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 01 Jun 2023 | 500 | 80,828 (0%) | 0% | 31 | 15,500 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 31.70 per share. | 01 May 2023 | 3,201 | 63,081 (0%) | 0% | 31.7 | 101,472 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 32.15 per share. | 03 Apr 2023 | 3,201 | 66,282 (0%) | 0% | 32.1 | 102,912 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.65 per share. | 15 Mar 2023 | 3,739 | 69,483 (0%) | 0% | 30.6 | 114,600 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 33.50 per share. | 01 Mar 2023 | 3,201 | 49,390 (0%) | 0% | 33.5 | 107,234 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.21 per share. | 15 Feb 2023 | 2,085 | 52,591 (0%) | 0% | 33.2 | 69,243 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 50,435 | 50,435 | - | - | Employee Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 34.60 per share. | 31 Jan 2023 | 3,201 | 54,676 (0%) | 0% | 34.6 | 110,755 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 20 Jan 2023 | 1,000 | 57,877 (0%) | 0% | 31 | 31,000 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 09 Jan 2023 | 1,701 | 60,877 (0%) | 0% | 25 | 42,525 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 09 Jan 2023 | 1,000 | 59,877 (0%) | 0% | 28 | 28,000 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 09 Jan 2023 | 1,000 | 58,877 (0%) | 0% | 30 | 30,000 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 12.18 per share. | 31 Dec 2022 | 645 | 62,578 (0%) | 0% | 12.2 | 7,856 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.50 per share. | 15 Dec 2022 | 1,557 | 61,933 (0%) | 0% | 21.5 | 33,476 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2022 | 42,349 | 91,739 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 22 Sep 2022 | 18,517 | 73,222 (0%) | 0% | 31.6 | 584,884 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 11.75 per share. | 30 Jun 2022 | 965 | 63,490 (0%) | 0% | 11.7 | 11,336 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.79 per share. | 15 Mar 2022 | 2,607 | 62,525 (0%) | 0% | 15.8 | 41,165 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.35 per share. | 15 Feb 2022 | 2,241 | 65,815 (0%) | 0% | 13.3 | 29,917 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.35 per share. | 15 Feb 2022 | 683 | 65,132 (0%) | 0% | 13.3 | 9,118 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 42,349 | 105,430 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Sale of securities on an exchange or to another person at price $ 34.55 per share. | 02 Feb 2022 | 21,401 | 84,029 (0%) | 0% | 34.5 | 739,338 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.97 per share. | 15 Feb 2021 | 1,973 | 68,762 (0%) | 0% | 29.0 | 57,158 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.97 per share. | 15 Feb 2021 | 684 | 70,735 (0%) | 0% | 29.0 | 19,815 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 40,925 | 40,925 | - | - | Employee Stock Option (Right to Buy) | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 22,620 | 71,419 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.75 per share. | 15 Dec 2020 | 1,556 | 48,306 (0%) | 0% | 26.8 | 41,623 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 15,750 | 55,308 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.14 per share. | 30 Sep 2020 | 5,446 | 49,862 (0%) | 0% | 25.1 | 136,912 | Common Stock |
| Revance Therapeutics Inc | Tobin C. Schilke | CFO | Other type of transaction at price $ 13.80 per share. | 30 Jun 2020 | 763 | 39,558 (0%) | 0% | 13.8 | 10,526 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges